TUESDAY, Oct. 17, 2023 (HealthDay News) — Solriamfetol seems to be effective for management of attention-deficit/hyperactivity disorder (ADHD) in adults, according to a study published online Oct. 9 in the Journal of Clinical Psychiatry.
Craig B. H. Surman, M.D., from Massachusetts General Hospital in Boston, and colleagues performed a remotely conducted, randomized, double-blind, six-week dose-optimization trial of 75 or 150 mg of solriamfetol in 60 adults with ADHD.
The researchers found that solriamfetol was well tolerated with no significant effect on mean heart rate, systolic blood pressure, or diastolic blood pressure. No significant treatment effect on the occurrence of adverse events was seen. Individuals on solriamfetol treatment experienced adverse events in several categories at a rate of at least 10 percentage points higher than individuals on placebo. By study end point, a significantly greater proportion of individuals in the treatment group met the a priori-defined treatment response (Clinical Global Impressions scale score indicating much or very much improved and Adult ADHD Investigator Symptom Rating Scale [AISRS] score reduced ≥25 percent: 45 versus 6.9 percent). Greater improvement in total AISRS scores by weeks 3 through 6 was also seen for those treated with solriamfetol. A 0.5 standard deviation improvement in T-score on the Behavior Rating Inventory of Executive Function-Adult Form Global Executive Composite occurred in significantly more solriamfetol-treated adults. In addition, they had greater mean change in the Global Assessment of Functioning score.
“Our findings offer hope of a new method of supporting the daily challenges that individuals with ADHD face,” Surman said in a statement.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2023 HealthDay. All rights reserved.
